NPPB and hydrops fetalis: Classically, the biomarkers used for identifying CTX during DOX treatment are cardiac troponins (cTn) isoforms I and T natriuretic peptides (NPs) [7], although N-terminal proB-type natriuretic peptide (NT-pro-BNP) is significantly associated with the presence of HF particularly in the late-stage DOX-induced cardiac impairment [8].